Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
bluebird bio announces take-private deal with Carlyle and SK Capital
Gene therapy developer bluebird bio (NASDAQ:BLUE) announced Friday its plans to become a privately held biotech as part of an M&A agreement with private equity firms, Carlyle Group (NASDAQ:CG) and SK ...
shorenewsnetwork2d
Owners of Controversial Trump Themed New Jersey Store Announce Closure, Plan for Future
The "Let’s Go Brandon" store, a polarizing retail fixture at 1405 Route 37 East in Toms River, New Jersey, has announced a ...
CF Industries' Low-Cost Nitrogen Production Should Remain Profitable as Prices Stabilize
CF Industries is the largest nitrogen producer in North America, with operations in the United States and Canada. CF's plants, which benefit from low-cost North American natural gas, are connected to ...
Global Blue: Takeover Offer Comes At Only A Slight Premium (Rating Downgrade)
Global Blue has entered into an agreement with Shift4 to be acquired at $7.5 per share. Preliminary Q3 results show that ...
Rule Breaker Investing: Old, New, Borrowed & Blue, Vol. 9
Every once in a blue moon, or a new moon, or an old moon or a borrowed moon, I queue up a hodgepodge of points that I want to ...
Why Blue Bird (BLBD) Remains a Solid Choice Despite Policy Uncertainty
Blue Bird Corporation (BLBD) recently announced fiscal Q1 results, beating top and bottom-line expectations. While the ...
Money blog: Britain's favourite banks revealed - and there's a new winner
Welcome back to the Money blog. We've kicked off the week by exploring what it's like to be a teacher - and it's not all lovely long holidays. Elsewhere, a quarter of employers say they're planning to ...